Профилактика кардиотоксического действия антрациклинового антибиотика доксорубицина: роль ингибитора ангиотензинпревращающего фермента периндоприла

Aim – to study how anthracyclines influence on cardiovascular system in patients with lymphomas and whether angiotensin-converting enzyme inhibitor Perindopril is cardioprotective in these patients. Subjects and methods . 26 patients with Hodgkin’s disease and non-Hodgkin’s lymphomas were followed before and after treatment with doxorubicin. 12 of these patients with arterial hypertension received angiotensin-converting enzyme inhibitor Рerindopril, 10 mg/d, during treatment with doxorubicin. Cardiological evaluation was performed before and the next day after chemotherapy. Average dose of Doxorubicin was 34,99 ± 13,23 mg/m2. Results. In patients receiving anthracyclines deceleration time DT increased significantly, a significant reduction in heart rate (HR), cardiac output (CO) and cardiac index (CI) were observed also (рDT = 0,037, pHR = 0,048, рСО = 0,007, рCI = 0,007). In patients simultaneously treated with Perindopril these parameters were not statistically different (рDT = 0,92, pHR = 0,22, рCO = 0,35, рCI = 0,39). Conclusion. Administration of anthracyclines (average dose of Doxorubicin 34,99 ± 13,23 mg/m2) leads to DT of the left ventricle and reduction in HR, CJ and CI. Simultaneous treatment with Perindopril in patients receiving anthracyclines preserves DF and prevents heart hemodynamics abnormalities.